C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests for Alzheimer’s Diagnosis
Specialty diagnostics company C2N Diagnostics has announced a strategic partnership with South Korea–based healthcare firm BeauBrain Healthcare to introduce advanced blood-based diagnostic testing for Alzheimer’s disease in South Korea. Through this collaboration, healthcare professionals in the country will gain access to C2N’s innovative PrecivityAD2 Blood Test, a breakthrough diagnostic tool designed to help physicians identify biological markers associated with Alzheimer’s disease earlier and more accurately.
The partnership marks an important step in expanding access to modern diagnostic technologies in Asia and highlights the growing global interest in blood-based testing solutions for neurodegenerative conditions. By bringing its Precivity portfolio to South Korea, C2N aims to support clinicians in diagnosing Alzheimer’s disease at earlier stages, when treatment decisions and disease management strategies can have the greatest impact on patient outcomes.
Expanding Access to Early Alzheimer’s Diagnostics
The PrecivityAD2 Blood Test is designed for individuals aged 50 and older who exhibit symptoms associated with mild cognitive impairment or dementia. These symptoms may include memory loss, difficulty concentrating, confusion, and other cognitive challenges that could indicate early-stage Alzheimer’s disease. The blood test measures biomarkers related to amyloid plaques—protein accumulations in the brain that are widely recognized as one of the key pathological hallmarks of the disease.
Amyloid plaques are believed to play a central role in the development and progression of Alzheimer’s disease. Detecting these plaques early can provide valuable insights into whether a patient’s cognitive symptoms may be related to the disease. The test therefore assists physicians in determining the most appropriate clinical management strategies and potential treatment pathways.
Traditionally, confirming the presence of amyloid plaques required specialized imaging techniques such as amyloid PET scans. While effective, these scans can be expensive, difficult to access, and involve exposure to radiation. Blood-based diagnostics offer a less invasive and more accessible alternative, making them particularly valuable for routine clinical practice and broader population screening.
Through the partnership with BeauBrain Healthcare, healthcare providers across South Korea—including neurologists, psychiatrists, internists, and family medicine physicians—will be able to incorporate the test into their diagnostic workflows.
Growing Interest Among South Korean Physicians
Recent survey results suggest strong interest among medical professionals in South Korea regarding blood-based Alzheimer’s diagnostics. According to data gathered during a webinar hosted for clinicians, approximately 72 percent of physicians indicated they would be willing to adopt blood-based diagnostic tests for Alzheimer’s disease once they become available in clinical practice.
Notably, this interest was not limited to specialists in neurology or psychiatry. Physicians in internal medicine and family medicine also expressed enthusiasm for the technology. Since primary care physicians are often the first point of contact for patients experiencing memory or cognitive concerns, their ability to use reliable diagnostic tools could significantly improve early detection rates.
The growing interest among South Korean physicians reflects a broader shift within the global healthcare community toward earlier and more precise detection of neurodegenerative diseases. As scientific advances continue to produce reliable biomarker-based tests, clinicians increasingly recognize the value of integrating these technologies into routine patient care.
Research Supporting the PrecivityAD2 Test
The diagnostic technology behind the PrecivityAD2 Blood Test incorporates advanced biomarker analysis, including measurement of the %p-tau217 biomarker. This biomarker has become an important focus in Alzheimer’s research because of its strong association with amyloid pathology in the brain.
Recent findings from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) program indicate that the %p-tau217 biomarker used in the test may be less affected by certain biological factors that can sometimes interfere with other diagnostic approaches. These confounding factors include body weight variations, kidney function issues, and anemia.
Because the biomarker appears less sensitive to these influences, the test may provide more stable and reproducible results in patients who have additional medical conditions. This reliability is especially valuable in real-world clinical environments, where patients frequently present with multiple health concerns.
The research findings have been published in leading peer-reviewed medical journals, including Journal of the American Medical Association and JAMA Neurology. Publication in these widely respected journals has helped reinforce the scientific credibility of blood-based Alzheimer’s diagnostics and has attracted considerable attention from the academic and clinical communities.
Leadership Perspectives on the Partnership
Leaders from both organizations emphasized the importance of the collaboration in improving global access to early diagnostic tools for Alzheimer’s disease.
Dr. Joel Braunstein, President and Chief Executive Officer of C2N Diagnostics, praised the shared mission behind the partnership. According to Braunstein, BeauBrain’s vision of creating “a world where all people can be free from the obscure fear of dementia” aligns closely with C2N’s commitment to innovation in brain health diagnostics.
He also noted that BeauBrain had many potential diagnostic partners to choose from, making their decision to adopt the PrecivityAD2 test particularly meaningful. The collaboration, Braunstein said, further confirms C2N’s growing role as a global leader in Alzheimer’s disease diagnostic testing.
BeauBrain Healthcare co-CEO Jae Hak Kim highlighted the critical role early diagnosis plays in managing the disease. According to Kim, early detection represents the entry point for effective prevention strategies aimed at slowing disease progression. Without a timely diagnosis, patients may lose valuable opportunities to benefit from interventions that could preserve cognitive function.
Kim explained that he co-founded BeauBrain Healthcare to help deliver innovative solutions that can be used in a wide range of healthcare settings. Partnering with C2N Diagnostics, he said, was a natural choice given the extensive scientific validation supporting the PrecivityAD2 blood test.
Rising Demand for Accurate Alzheimer’s Diagnosis
The demand for accessible diagnostic tools has grown significantly in recent years, particularly as new treatment options for Alzheimer’s disease have begun to emerge.
Regulatory authorities, including the U.S. Food and Drug Administration and South Korea’s Ministry of Food and Drug Safety, have recently approved disease-modifying therapies that target the biological mechanisms believed to drive Alzheimer’s disease. These therapies aim to slow or alter the progression of dementia by addressing the underlying accumulation of amyloid plaques in the brain.
However, the effectiveness of such treatments depends heavily on identifying appropriate patients early in the disease process. Accurate diagnostic tests are therefore essential to ensure that patients who may benefit from these therapies can be identified and treated promptly.
Blood-based diagnostics like the PrecivityAD2 test have the potential to play a critical role in this evolving treatment landscape by providing physicians with a practical and scalable method for detecting amyloid pathology.
Clinical Evidence Demonstrating Test Performance
Multiple clinical studies have evaluated the performance of the PrecivityAD2 Blood Test in real-world clinical settings.
A large clinical study published in the Journal of the American Medical Association found that incorporating the test into the diagnostic process improved the accuracy of Alzheimer’s disease diagnosis compared with standard care without biomarker testing.
Importantly, this improvement was observed in both primary care and specialized clinical environments. Because many individuals first report memory problems to their primary care physicians, the availability of reliable diagnostic tools in these settings could significantly improve the timeliness of Alzheimer’s detection.
Additional research published in the scientific journal npj Dementia—part of the Nature Portfolio—further demonstrated the test’s strong performance characteristics. According to the study, the blood test achieved approximately 91 percent overall accuracy when compared with amyloid PET imaging, which is currently considered one of the most reliable methods for detecting amyloid plaques.
The study also reported sensitivity of around 90 percent and specificity of approximately 92 percent using the test’s established clinical cutoff values. These results support C2N’s assertion that the test offers repeatable, reliable, and robust diagnostic performance.
Regulatory Recognition and Global Expansion
The innovative nature of C2N’s technology has also received recognition from regulatory authorities. The company’s proprietary blood test for detecting brain amyloidosis has been granted Breakthrough Device designation by the U.S. Food and Drug Administration. This designation is intended to accelerate the development and review of medical devices that have the potential to provide significant improvements in diagnosing or treating serious medical conditions.
In addition, the diagnostic test has received medical device registration from the Medicines and Healthcare products Regulatory Agency in the United Kingdom, further supporting its growing international adoption.
Strategic Investment from Samsung
C2N Diagnostics has also attracted support from major industry partners. In 2025, the company announced a $10 million investment from several entities affiliated with Samsung Group, including Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation.
The investment was intended to help expand C2N’s clinical laboratory services and accelerate the development and global distribution of its diagnostic technologies. With support from these organizations, C2N aims to further advance research and innovation in brain health diagnostics while expanding access to its testing platforms around the world.
Supporting Healthcare Providers in South Korea
As the partnership with BeauBrain Healthcare moves forward, healthcare providers in South Korea will have the opportunity to integrate the PrecivityAD2 test into their clinical practices. The availability of a simple blood test could help clinicians more confidently evaluate patients presenting with cognitive symptoms and determine whether further neurological assessment or treatment is appropriate.
Doctors’ offices interested in learning more about the test or implementing it within their practice can contact BeauBrain Healthcare directly for additional information.
Advancing the Future of Alzheimer’s Care
The introduction of blood-based diagnostics represents a significant step toward transforming how Alzheimer’s disease is detected and managed. By enabling earlier and more accurate identification of disease-related biomarkers, technologies such as the PrecivityAD2 Blood Test could help physicians intervene sooner and potentially improve long-term outcomes for patients.
Through collaborations like the one between C2N Diagnostics and BeauBrain Healthcare, innovative diagnostic tools are becoming increasingly accessible to healthcare providers worldwide—bringing the medical community closer to a future where Alzheimer’s disease can be diagnosed earlier, treated more effectively, and ultimately better managed for millions of patients.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories. Over 90,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
About BeauBrain Healthcare
Founded by world-renowned scientists and neurologists Dr. Na (Duk L.) and Dr. Seo (Sang Won) from Samsung Medical Center, in collaboration with Mint Venture Partners, BeauBrain Healthcare is building a holistic platform to lead the new era of early Alzheimer’s disease intervention. The company’s integrated solution encompasses digital cognitive assessments, AI-powered brain imaging analysis, cognitive training, and blood biomarker algorithms powered by C2N.
